Collectively, these results demonstrate an important role of the FABP3-PPARα pathway on fuel preference and cardiac hypertrophy, while treatment with fenofibrate may reverse hypertrophy, suggesting the potential clinical value for fenofibrate in hypertrophic treatment (Figure 8). The gene discussed is PPARA; the disease is cardiac hypertrophy.